Details

Autor(en) / Beteiligte

• Bernard-Valnet, Raphaël
• Lalive, Patrice H
• Bréville, Gautier
• Théaudin, Marie
• Pot, Caroline
• Du Pasquier, Renaud

Titel

Discontinuing disease-modifying therapies in multiple sclerosis

Ist Teil von

• Revue médicale suisse, 2024-04, Vol.20 (871), p.843

Ort / Verlag

Switzerland

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• Aging in multiple sclerosis (MS) leads to altered clinical manifestations, where the pathophysiology shifts towards compartmentalized inflammation that drives clinical progression independent of relapse activity. Consequently, the effectiveness of disease-modifying therapies (DMTs) diminishes in older patients, coinciding with an elevated risk of adverse events. This raises the question of whether MS therapies should be discontinued after a certain age, which is often proposed for patients over 55 years. Studies on treatment discontinuation have shown a slight increase in disease activity, yet without significant disability progression. This suggests that the decision to stop DMTs should be discussed with older patients, considering existing comorbidities. Following the cessation of therapy, meticulous monitoring is essential.